Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FM8HW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on September 9, 2025, carries an ultimate completion date of September 30, 2025, with no set-aside designation applied. The contract represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to issue delivery orders for a comprehensive portfolio of pharmaceutical products supporting Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group leverages its established position as a critical supplier in the federal pharmaceutical supply chain, having maintained federal contracting relationships since its SAM.gov registration in 2001. The company specializes in distributing branded and generic prescription drugs, biologics, and medical consumables directly to military and federal healthcare facilities. This delivery order for Xolair, a pharmaceutical treatment typically used for moderate to severe allergic asthma and chronic idiopathic urticaria, exemplifies the company's role in providing specialized injectable medications that support the operational health readiness requirements of Department of Defense personnel and beneficiaries.
Quick answers
Who was awarded contract SPE2DB25FM8HW?
SPE2DB25FM8HW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 9, 2025.
How much is contract SPE2DB25FM8HW worth?
The government has obligated $10,273 on SPE2DB25FM8HW.
Is contract SPE2DB25FM8HW an order under another contract?
Yes. SPE2DB25FM8HW is a delivery order under SPE2DB22D9151, an indefinite delivery contract.
Was contract SPE2DB25FM8HW competed?
The extent of competition for SPE2DB25FM8HW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award